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Abstract
The common 2652 6N del variant in the CASP8 promoter (rs3834129) has been described as a putative low-penetrance risk
factor for different cancer types. In particular, some studies suggested that the deleted allele (del) was inversely associated
with CRC risk while other analyses failed to confirm this. Hence, to better understand the role of this variant in the risk of
developing CRC, we performed a multi-centric case-control study. In the study, the variant 2652 6N del was genotyped in a
total of 6,733 CRC cases and 7,576 controls recruited by six different centers located in Spain, Italy, USA, England, Czech
Republic and the Netherlands collaborating to the international consortium COGENT (COlorectal cancer GENeTics). Our
analysis indicated that rs3834129 was not associated with CRC risk in the full data set. However, the del allele was under-
represented in one set of cases with a family history of CRC (per allele model OR = 0.79, 95% CI = 0.69–0.90) suggesting this
allele might be a protective factor versus familial CRC. Since this multi-centric case-control study was performed on a very
large sample size, it provided robust clarification of the effect of rs3834129 on the risk of developing CRC in Caucasians.
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Introduction
Carcinogenesis is characterized by the alteration of the normal
processes designated to maintain the genome stability. Apoptosis is
the most prominent mechanism of the programmed cell-death,
responsible for the safe removal of damaged cells before genome
abnormalities can be replicated and further spread. Caspase
enzymes are essential in the regulation and execution of most of
the apoptotic cell-death pathways. In particular, caspase-8 (CASP8)
is a crucial player in controlling the apoptosis of T lymphocytes
through activation-induced cell-death [1] and, simultaneously, a
physiological homeostasis of T lymphocytes is a fundamental
aspect in the immune-surveillance of cancer cells.
A polymorphism consisting of the deletion of six nucleotides in
the promoter region of CASP8, and referred as –652 6N del
(rs3834129), has been described to be very common in several
populations [2]. This six-nucleotide deletion was shown to destroy
a stimulatory protein 1 binding element in the promoter
regulatory region that causes a decreased CASP8 transcription
and eventually a reduced apoptosis of antitumor T lymphocytes
[2]. Thus, rs3834129 was postulated to affect the antitumor
immune response during cancer initiation or progression, and
consequently considered as a genetic factor potentially associated
with cancer risk. In this light, the polymorphism was tested in a
case-control study and the del allele was shown to be associated
with a protective effect in several types of cancer, including CRC,
in the Chinese population [2]. Two subsequent studies further
investigated the effect of rs3834129 in CRC testing cases and
controls of mixed and Caucasian ethnicity but failed to confirm
the association [3,4]. A meta-analysis of these three studies
indicated that, under a dominant model, the del allele was
associated with a significantly reduced risk for CRC with odds
ratio (OR) = 0.89, 95% confidence interval (CI) = 0.83–0.96 [5].
However, a later study not included in the above meta-analysis,
again failed to reveal an association between rs3834129 and CRC
risk in Chinese [6].
Hence, in the present study we sought for more robust proof,
whether rs3834129 may be a CRC risk factor in a case-control
study, based on six cohorts recruited in centers located in Spain,
Italy, USA, England, Czech Republic and the Netherlands and




The COGENT (COlorectal cancer GENeTics) consortium was
established in 2007 with the main goal to study genetic
susceptibility to CRC in a collaborative way. The consortium
consisted in over 20 research groups in Europe, Australia, the
Americas, China and Japan actively working on CRC genetics and
with expertise encompassing genetic epidemiology, statistical
genetics, gene mapping, biology, molecular genetics, pathology
and diagnosis and the clinical management of CRC [8]. Maintain-
ing its main objectives, the consortium has now evolved into a
more structured initiative named ‘‘Cooperation Studies on Inher-
ited Susceptibility to Colorectal Cancer’’ (EuCOLONGENE -
http://www.eucolongene.eu). In the present study, rs3834129 was
tested as genetic risk factor for CRC in six cohorts comprising 6,733
cases and 7,576 controls.
1. Spanish cohort. Cases and controls were recruited through
the EPICOLON Consortium that is based on a prospective,
multicenter and population-based epidemiology survey of the
incidence and features of CRC in the Spanish population [9].
Briefly, cases were selected as patients with de novo histologically
confirmed diagnosis of colorectal adenocarcinoma. Exclusion
criteria were hereditary CRC forms, such as hereditary non-
polyposis colorectal cancer (HNPCC) and familial adenomatous
polyposis (FAP) and a personal history of inflammatory bowel
disease. Controls were from the Spanish National DNA bank and
were confirmed not to have cancer or history of neoplasm and no
family history of CRC. All cases and controls were of Caucasian
ethnicity. 2. Italian cohort. Cases and controls were recruited as
described by [10]. Briefly, the cases were consecutive individuals
affected with CRC who underwent surgery at the Fondazione
IRCCS Istituto Nazionale Tumori in Milan (INT). The controls
were blood donors recruited through the Immunohematology and
Transfusion Medicine Service of INT the Associazione Volontari
Italiani Sangue Comunale in Milan. All cases and controls were of
Caucasian ethnicity. 3. American cohort (Kentucky, USA). Cases
and controls were recruited as recently described [11]. Briefly,
incident colon cancer cases were identified through the Kentucky
Cancer Registry. Population controls were recruited via random
digit dialing according to the following criteria: being at least 30
years of age or older and free of personal history of cancer other
than skin cancer. For both cases and controls, exclusion criteria
were inflammatory bowel diseases, FAP and HNPCC. Majority of
the participants were Caucasians (93.7%). 4. English cohort. Cases
(CRC or significant adenomas) and controls were recruited
through Colorectal Tumour Gene Identification (CoRGI) consor-
tium as previously described [12]. Briefly, cases had at least one
first-degree relative affected by CRC. The controls were spouses
or partners unaffected by cancer and without a personal and
family history of colorectal neoplasia. A single proband from each
family was included in this study. Hereditary CRC forms such as,
HNPCC/Lynch syndrome or bi-allelic MutYH mutation carriers
were excluded. All cases and controls were of Caucasian ethnicity.
5. Czech Republic cohort. Cases and controls were recruited as
previously described [13]. Briefly, all cases had histologically
confirmed CRC and were consecutively ascertained through
oncological departments. Controls were either hospital-based
volunteers with negative colonoscopy results or blood donors
collected from a blood donor center in Prague. All cases and
controls were of Caucasian ethnicity. 6. Dutch Cohort. Cases and
controls were recruited as previously described [14]. Briefly, most
of the cases were recruited through the clinical genetics
department. All cases were diagnosed with CRC and had early
onset and/or positive family history for CRC. Known dominant
polyposis syndromes, HNPCC/Lynch syndrome or bi-allelic
MutYH mutation carriers were excluded. A single proband from
each family was included in this study. Controls were healthy
blood donors from the southwest region of the Netherlands. All
cases and controls were of Caucasian ethnicity.
For each cohort, number of cases and controls included in the
study and their sex and age data are shown in Table 1. All
individuals participating in this study signed an informed consent
to the use of their biological samples for research purposes. This
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study was approved by the following Institutions: Clinical
Research Ethics and Research Committees of the Hospital Clı́nic
in Barcelon (Spanish cohort); Ethics Committee of Fondazione
IRCCS Istituto Nazionale dei Tumori, Milan, Italy (Italian
cohort); Institutional Review Boards of the University of
Kentucky, Lexington, Case Western Reserve University/Univer-
sity Hospitals of Cleveland and University of Southern California,
USA (American cohort); Southampton and South-West Hamp-
shire Research Ethics Committee (English cohort); Ethics Com-
mittee of the Institute of Experimental Medicine, and Ethics
Committee of the Institute for Clinical and Experimental
Medicine and Thomayer Hospital, Prague, Czech Republic
(Czech Republic cohort); the Medical Ethical Committee of the
Leiden University Medical Center, The Netherlands (protocol
P01.019) (Dutch cohort).
Genotyping
The genomic DNA was isolated from peripheral blood
lymphocytes using standard procedures. The DNA samples from
cases and controls were randomly aliquot in 96-well plates.
Genotyping of the rs3834129 was carried out by using the
Taqman assay (Life Technologies/Applied Biosystems, US) in the
Spanish, Italian, USA and Dutch cohorts and using the KASPar
assay (K-bioscience, UK) in the English and Czech Republic
cohorts. Duplicate samples (5%), no template controls in each
plate, and Hardy–Weinberg equilibrium test were used as quality
control tests.
Statistical analysis
Within each cohort, a logistics regression analysis [15] was
carried out in order to compare the genotypes frequency of CASP8
rs3834129 in cases and controls. We estimated the odds ratio (OR)
and their relative 95% confidence interval (CI) by considering in
each logistic model age and sex as adjustment covariates. Four
different models (‘‘three genotypes’’, dominant, recessive and per
allele) were performed for each cohort separated and considering
all the individuals together. In this case, the variable with the
indication of the cohort and the interaction term between this
variable and the genotype were included in the logistic model in
addition to the variables genotype, age and sex. The deviations of
the genotype frequencies in the controls from those expected
under Hardy-Weinberg equilibrium (HWE) were assessed within
each cohort as well as by considering all individuals using
Pearson’s chi-squared test. All statistical analyses were performed
with the SAS software (Version 9.2; SAS Institute Inc. Cary, NC).
Results and Discussion
In this study, we analyzed the rs3834129 genotype distribution
in a total of 6,733 cases and 7,576 controls from six cohorts, all of
Caucasian ethnicity. The genotype distributions in controls were
consistent with HWE in all the cohorts and across them the
frequencies of the del allele were similar in controls (range: 0.45–
0.52). We performed an overall analysis to compare the genotypes
frequency of CASP8 rs3834129 in cases with CRC and in healthy
controls. As in the Dutch controls data on sex and/or age were
missing (Table 1), this cohort was excluded from the overall
analysis and a total of 6,148 cases and 7,217 controls were
considered. All cohorts were based on incident/consecutive cases
except for the English cohort which was based on familial cases.
Therefore, we also performed an additional overall analysis
excluding the English cohort and testing a total of 4,572 cases
and 6,450 controls. In both these analyses the interaction term
between cohort and genotype was not statistically significant and
also the ORs derived from the different implemented genetic
models were not statistically significant (data not shown).
Furthermore, we assessed the effect of rs3834129 on CRC risk
within each cohort. The OR estimates were adjusted for sex and
age with the only exception of Dutch cohort, results are reported
in Table 2. The ORs of the different implemented models (three
genotypes, dominant, recessive and per-allele model) largely
confirmed the results of the overall analysis being non statistically
significant in each cohort with the only exception of the English
one. The ORs in familial case-control samples from England were
statistically significant (per allele model OR = 0.79, 95%
CI = 0.69–0.90) indicating the del allele might be a protective
factor versus familial cancer. This result may be explained
considering that the familial cases, with respect to incident/
consecutive cases, can be a better resource for association testing
since they are expected to be enriched by genetic risk factors, or
conversely, deprived by factors with a protective effect.
To our knowledge, this is the largest analysis testing the
association between rs3834129 and CRC risk in Caucasians and
our data provide the stronger and unambiguous evidence so far
that the rs3834129 is not a CRC risk factor in this ethnic group.
While our analysis was ongoing, other studies appeared, showing
inconsistent results. On one side, lack of association was found in
case-control analyses based on Greek and Chinese populations
[16,17]; on the other side, a meta-analysis, based on three studies
of mix ethnicity, and a separate additional study on Chinese
showed a moderately protective effect of the del allele [18,19]. Our
findings in Caucasians, with respect to the putative protective
effect detected in Chinese—that has to be confirmed by further
larger studies—might be explained by additional risk-associated
variants in linkage with rs3834129 and with different frequency in
different ethnic genetic backgrounds. Specifically, the del allele of
rs3834129 has a 0.48 control frequency in our study while we
derived a frequency of 0.20–0.25 in Chinese controls [2,6,16,18].
In conclusion, while further studies are needed to confirm the
protective effect of the del allele we observed in familial CRC cases
with family history, our study provides robust evidence indicating
the rs3834129 is not a risk factor for CRC in Caucasians.
Table 1. Characteristics of the cohorts included in the study.
Cohort Group N Age Female (%) Male (%)
min median max
Spanish Case 1978 26 72 101 778 (39.3) 1200 (60.7)
Control 1647 19 66 95 748 (45.4) 899 (54.6)
Italian Case 617 24 64 91 243 (39.4) 374 (60.6)
Control 2551 18 44 71 1619 (63.5) 932 (36.5)
USA Case 1010 23 65 90 501 (49.6) 509 (50.4)
Control 1580 31 61 91 1017 (64.4) 563 (35.6)
English Case 1576 18 65 89 712 (45.2) 864 (54.8)
Control 767 18 56 86 462 (60.2) 305 (39.8)
Czech Rep. Case 967 26 62 89 393 (40.6) 574 (59.4)
Control 672 24 57 91 314 (46.7) 358 (53.3)
Dutch Case 585* 19 52 90 293 (50.1) 261 (44.6)
Control 359 NA NA NA
*Data on sex were missing for 31 cases.
doi:10.1371/journal.pone.0085538.t001
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(EPICOLON I local coordinator), Rodrigo Jover (EPICOLON II local
coordinator), Cristina Alenda, Laura Sempere, Nuria Acame, Estefanı́a Rojas,
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